JVJoanne L. Viney

Joanne L. Viney

*This is an algorithmically generated author record based on publicly available information.

Joanne L. Viney has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Gatekeepers of intestinal inflammation

    by Heather A. Arnett, Joanne L. Viney

    The intestine is subjected to a barrage of insults from food, bacterial flora, and pathogens. Despite this constant antigenic challenge, the mucosal tissues lining the intestinal tract remain largely under control. The mechanisms regulating the homeostatic balance in the gut have been investigated for many years by many groups, but the precise nature of the regulatory control remains elusive. In this review, we provide an overview of pathways proposed to be involved in dampening the inflammatory response and maintaining the homeostatic balance in the intestine, and how these pathways may be disrupted in ulcerative colitis and Crohn’s disease.


    • 1 May 2009
      • Vol. 10  (5) , 443-51

    Recent developments in IBD and the B7 family of costimulatory molecules.

    by Heather A Arnett, Joanne L Viney

    The cells and tissues of the intestinal tract are subjected to a constant onslaught of antigenic challenge from both beneficial and harmful pathogens. Despite this constant stimulation, the host is able to maintain a relatively stable environment, often referred to as 'a controlled state of inflammation'. In patients with chronic inflammatory bowel disease, this controlled state of inflammation is lost. The cause of this loss of control is not fully understood, but there is emerging research interest in positive and negative costimulatory pathways as potential targets for modulating the dysregulation. This review describes the B7 and B7-like butyrophilin families of costimulatory molecules, with an emphasis on the role of costimulation in intestinal inflammation.


  • The mdr1a–/– Mouse Model of Spontaneous Colitis: A Relevant and Appropriate Animal Model to Study Inflammatory Bowel Disease

    by Jacque N. Wilk, Janine Bilsborough, Joanne L. Viney

    There are many types of colitis models in animals that researchers use to elucidate the mechanism of action of human inflammatory bowel disease (IBD). These models are also used to test novel therapeutics and therapeutic treatment regimens. Here, we will review the characteristics of the mdr1a−/− model of spontaneous colitis that we believe make this model an important part of the IBD researcher's toolbox. We will also share new data that will reinforce the fact that this model is relevant in the study of IBD. Mdrla−/− mice lack the murine multiple drug resistance gene for P-glyco-protein 170 that is normally expressed in multiple tissues including intestinal epithelial cells. These mice spontaneously develop a form of colitis at around 12 wk of age. The fact that the complexity of this model mirrors the complexity of disease in humans, as well as recent literature that links MDR1 polymorphisms in humans to Crohn's Disease and Ulcerative Colitis, makes this an appropriate animal model to study.


  • In Vivo Enhancement of Dendritic Cell Function

    by Janine Bilsborough, Joanne L. Viney

    Abstract: Despite the apparent positive recognition of antigen by mucosal T cells after ingesting food, the default functional response in the gut is tolerance. Although dendritic cells (DCs) are classically defined as potent stimulatory antigen‐presenting cells, we have previously shown that tolerance is enhanced in vivo in the presence of elevated numbers of DCs. In order to more closely investigate the mechanistic basis of tolerance induction, we have focused our subsequent studies on identifying features peculiar to mucosal dendritic cells and the functional involvement of mucosal DCs in driving the early T cell response to fed antigen. These studies have revealed a population of DCs in the mucosae that exhibit the plasmacytoid phenotype and secrete IFN‐α following stimulation with CpG, and can drive differentiation of naive T cells into cells that exhibit regulatory properties. The activity of these DCs also failed to sustain robust T cell proliferation and, rather, functioned to enhance the suppressive efficacy of CD4+CD25+ T regulatory cells. Given their significant presence in mucosal tissue, these DCs likely provide a mechanistic basis for the homeostatic regulation prominent in the gut, presumably by eliciting regulatory cell suppressor function and poorly supporting T helper cell proliferation. These studies further underscore the critical role for intestinal DCs in promoting tolerogenic antigen presentation at a site of high antigenic stimulation.


  • Out, out darn toxin: the role of MDR in intestinal homeostasis

    by Janine Bilsborough, Joanne L. Viney


  • Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties

    by Janine Bilsborough, Thaddeus C. George, Anne Norment, Joanne L. Viney

    Summary: Repetitive stimulation of naïve T cells by immature splenic dendritic cells (DC) can result in the differentiation of T‐cell lines with regulatory properties. In the present study we identified a population of DC in the mucosae that exhibit the plasmacytoid phenotype, secrete interferon‐α (IFN‐α) following stimulation with oligodeoxynucleotides containing certain cytosine‐phosphate‐guanosine (CpG) motifs and can differentiate naïve T cells into cells that exhibit regulatory properties. Although these DC appear to be present in both spleen and mesenteric lymph nodes (MLN), only CpG‐matured DC from the MLN (but not the spleen) were able to differentiate naïve T cells into T regulatory 1‐like cells with regulatory properties. The activity of these DC failed to sustain robust T‐cell proliferation and thereby enhanced the suppressive efficacy of CD4+ CD25+ T regulatory cells. These DC are the major CD8α+ DC population in the Peyer's patches (PP). Given their significant presence in mucosal tissue, we propose that these DC may provide a mechanistic basis for the homeostatic regulation in the gut by eliciting regulatory cell suppressor function and poorly supporting T helper cell proliferation at a site of high antigenic stimulation like the intestine.


    • 1 September 2002
      • Vol. 3  (9) , 1291-6

    GM-CSF treatment for Crohn's disease: a stimulating new therapy?

    by Jacque N Wilk, Joanne L Viney

    Crohn's disease (CD) has been classically viewed as an overactive intestinal immune response to the normal constituents of the gut flora. Most therapeutic strategies to date have tried to suppress this overactive adaptive immune response. Recently, a novel, rather alternative therapeutic strategy has been proposed, wherein the approach is to stimulate the innate immune system with growth factors. This review will take a closer look at this unconventional hypothesis and the data that support it, and will place the information in the context of some of the other biological and experimental therapies currently under consideration for the treatment of CD.